Kala Bio Inc (NAS:KALA)
$ 6.865 0.0486 (0.71%) Market Cap: 19.34 Mil Enterprise Value: 4.63 Mil PE Ratio: 0 PB Ratio: 2.51 GF Score: 51/100

Kala Pharmaceuticals, Inc. - Special Call Transcript

Sep 17, 2020 / 12:00PM GMT
Release Date Price: $437 (+1.51%)
Operator

Good morning and welcome to the Kala Pharmaceuticals investor and analyst event. (Operator Instructions) I would now like to turn the call over to Niranjan Kameswaran, Senior Vice President of Strategy for Kala Pharmaceuticals. Please proceed.

Niranjan Kameswaran
Kala Pharmaceuticals, Inc. - SVP of Strategy

Thank you, operator, and thank you, everyone, for joining us today. Today's event will focus on EYSUVIS, our product candidate for the short-term treatment of dry eye disease and is being webcast live. The audio webcast link along with the slides for today's presentation can be found in the Events page on the Investors section of our website, Kalarx.com. Please open the slides now. We kindly ask that you manually advance the slides as the speakers move through the presentation.

On this call, we will make certain comments about Kala's future expectations, plans and prospects that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements will include information regarding the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot